other_material
confidence high
sentiment positive
materiality 0.90
Altimmune's pemvidutide Phase 2b MASH trial hits primary endpoint; 59.1% resolution vs 19.1% placebo (p<0.0001)
Altimmune, Inc.
- MASH resolution without worsening fibrosis: 59.1% (1.2mg) and 52.1% (1.8mg) vs 19.1% placebo (p<0.0001).
- Fibrosis improvement not significant on primary, but AI analysis showed 30.6% achieving ≥60% reduction (p<0.001).
- Weight loss of 5.0% (1.2mg) and 6.2% (1.8mg) vs 1.0% placebo (p<0.001); trajectory not plateauing at 24 weeks.
- AE-related discontinuations <1.2% in pemvidutide arms vs 2.4% placebo; no SAEs related to study drug.
item 7.01item 8.01item 9.01